BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow ® disease ...
Lantheus is growing revenue and earnings at an above-average pace. The strong pipeline of Phase 3 compounds can sustain growth for multiple years. The attractive low valuation and strong growth makes ...
Alzheon Inc. has raised $100 million in a series E financing round to push its oral drug candidate for early Alzheimer’s disease (AD), ALZ-801 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback